CCL

Összesen 10 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM070510
Első szerző:Carvalho, Jozelio F.
Cím:Anti-Vitamin D, Vitamin D in SLE : preliminary Results / Carvalho J. F., Blank M., Kiss E., Tarr T., Amital H., Shoenfeld Y.
Dátum:2007
ISSN:0077-8923
Megjegyzések:The aim of this study was to detect antibodies to vitamin D in systemic lupus erythematosus (SLE) and other autoimmune diseases. The results may shed light to a novel aspect of vitamin D deficiency in autoimmune diseases. Sera from 171 patients with SLE, 56 with antiphospholipid syndrome (APS), and 18 with pemphigus vulgaris (PV) were studied employing an enzyme-linked immunosorbent assay for anti-vitamin D antibodies along with 94 healthy blood donors. In parallel, vitamin D concentrations in the serum were determined by a DiaSorin commercial kit (LIAISON 25 OH vitamin D). Antibody-positive and antibody-negative individuals were compared with respect to demographic variables, SLE disease activity index (SLEDAI) score, autoantibodies profile, and serum vitamin D levels. Anti-vitamin D antibodies were detected in 7 (4%) of 171 patients with SLE, in 2 (3.5%) of 56 of sera from patients with APS, and in 2 (11%) of 18 sera from patients with PV. Vitamin D levels were similar in both SLE groups with and without anti-vitamin D antibodies. Demographic features, organ involvement, SLEDAI score, and autoantibodies did not differ between the groups. Except for anti-dsDNA antibodies, in which anti-vitamin D antibodies were strongly associated with these antibodies in sera from SLE patients (P = 0.0004). Anti-vitamin D antibodies are observed in a subset of patients with SLE, APS, and PV, and are associated with anti-dsDNA antibodies in SLE. Further studies are required to explore the potential diagnostic and prognostic role of these novel antibodies in SLE.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
vitamin D
anti-vitamin D
autoantibodies
SLE
antiphospholipid syndrome
pemphigus vulgaris
Megjelenés:Annals Of The New York Academy Of Sciences 1109 : 1 (2007), p. 550-557. -
További szerzők:Blank, Miri Kiss Emese (1960-) (belgyógyász, immunológus) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Amital, Howard Shoenfeld, Yehuda
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM038593
Első szerző:Cervera, Ricard
Cím:Antiphospholipid syndrome : clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients / Ricard Cervera, Jean-Charles Piette, Josep Font, Munther A. Khamashta, Yehuda Shoenfeld, Maria Teresa Camps, Soren Jacobsen, Gabriella Lakos, Angela Tincani, Irene Kontopoulou-Griva, Mauro Galeazzi, Pier Luigi Meroni, Ronald H. W. M. Derksen, Philip G. de Groot, Erika Gromnica-Ihle, Marta Baleva, Marta Mosca, Stefano Bombardieri, Frédéric Houssiau, Jean-Christophe Gris, Isabelle Quéré, Eric Hachulla, Carlos Vasconcelos, Beate Roch, Antonio Fernández-Nebro, Marie-Claire Boffa, Graham R. V. Hughes, Miguel Ingelmo, Euro-Phospholipid Project Group
Dátum:2002
ISSN:0004-3591
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis And Rheumatism 46 : 4 (2002), p. 1019-1027. -
További szerzők:Piette, Jean-Charles Font, Josep Khamashta, Munther A. Shoenfeld, Yehuda Camps, Maria Teresa Jacobsen, Soren Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Tincani, Angela Kontopoulou-Griva, Irene Galeazzi, Mauro Meroni, Pier Luigi Derksen, Ronald H. W. M. de Groot, Philip G. Gromnica-Ihle, Erika Baleva, Marta Mosca, Marta Bombardieri, Stefano Houssiau, Frédéric Gris, Jean-Christophe Quéré, Isabelle Hachulla, Eric Vasconcelos, Carlos Roch, Beate Fernández-Nebro, Antonio Boffa, Marie-Claire Hughes, Graham R. V. Ingelmo, Miguel Soltész Pál (1961-) (belgyógyász, kardiológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Euro-Phospholipid Project Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM011672
Első szerző:Cervera, Ricard
Cím:Morbidity and mortality in the andiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients / Cervera R., Khamashta M. A., Shoenfeld Y., Camps M. T., Jacobsen S., Kiss E., Zeher M., Tincani A., Kontopoulou-Griva I., Galeazzi M., Bellisai F., Meroni P. L., Derksen R. H., de Groot P. G., Gromnica-Ihle E., Baleva M., Mosca M., Bombardieri S., Houssiau F., Gris J. C., Quéré I., Hachulla E., Vasconcelos C., Roch B., Fernández-Nebro A., Piette J. C., Espinosa G., Bucciarelli S., Pisoni C. N., Bertolaccini M. L., Boffa M. C., Hughes G. R., Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)
Dátum:2009
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals of the Rheumatic Diseases 68 : 9 (2009), p. 1428-1432. -
További szerzők:Khamashta, Munther A. Shoenfeld, Yehuda Camps, Maria Teresa Jacobsen, Soren Kiss Emese (1960-) (belgyógyász, immunológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Tincani, Angela Kontopoulou-Griva, Irene Galeazzi, Mauro Bellisai, F. Meroni, Pier Luigi Derksen, Ronald H. W. M. de Groot, Philip G. Gromnica-Ihle, Erika Baleva, Marta Mosca, Marta Bombardieri, Stefano Houssiau, Frédéric Gris, Jean-Christophe Quéré, Isabelle Hachulla, Eric Vasconcelos, Carlos Roch, Beate Fernández-Nebro, Antonio Piette, Jean-Charles Espinosa, G. Bucciarelli, S. Pisoni C. N. Bertolaccini, M. L. Boffa, Marie-Claire Hughes, Graham R. V. Euro-Phospholipid Project Group
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM020653
Első szerző:Kiss Emese (belgyógyász, immunológus)
Cím:Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients / Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., Shoenfeld Y., Szegedi G.
Dátum:2006
Megjegyzések:Systemic lupus erythematosus is associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Objectives were to determine endothelial dysfunction with a non-invasive method in lupus patients and to analyse correlation with risk factors and atherosclerotic complications. Sixty-one SLE patients and 26 healthy age- and sex-matched control subjects were entered into the study. The diameters of brachial artery at rest, during reactive hyperaemia, and after glyceril trinitrate administration, as well as the intima-media thickness of the common carotid artery were measured using high-resolution B-mode ultrasonography. Demographic characteristics, lipid profile, paraoxonase activity, concentration of anti-phospholipid antibodies and anti-oxLDL were assessed together with atherosclerotic complications. The endothelium dependent vasodilation (FMD) was significantly impaired in SLE patients as compared to controls. The absolute difference of vessel diameter (Deltad) was 0.25+/-0.15 mm vs. 0.38+/-0.16 mm (p=0.001), and Deltad as in percent of the rest diameter was 7.31+/-5.2% vs. 9.86+/-3.87% (p=0.013) in lupus patients and controls, respectively. Nitrate mediated dilation (NMD) did not differ. FMD negatively correlated with age, systolic and diastolic blood pressure in SLE, but did not show significant correlation with the other examined parameters. However, FMD significantly differed between SLE patients with (5.54+/-4.36%) and without (8.81+/-5.28%) cardiovascular complications (p=0.01). The determination of flow-mediated vasodilation is a useful method to detect endothelial dysfunction in lupus patients, as reduced capacity of brachial artery may distinguish between SLE patients and healthy subjects, as well as lupus patients with and without atherosclerotic vascular complications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Autoimmunity. - 27 : 4 (2006), p. 211-217. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Dér Henrietta (1977-) (orvos) Kocsis Zsolt (1987-) (orvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

5.

001-es BibID:BIBFORM015838
Első szerző:Orbach, Hedi
Cím:Prolactin and Autoimmunity : hyperprolactinemia Correlates with Serositis and Anemia in SLE Patients / Orbach, H., Zandman-Goddard, G., Boaz, M., Agmon-Levin, N., Amital, H., Szekanecz, Z., Szucs, G., Rovensky, J., Kiss, E., Doria, A., Ghirardello, A., Gomez-Arbesu, J., Stojanovich, L., Ingegnoli, F., Meroni, P. L., Rozman, B., Blank, M., Shoenfeld, Y.
Dátum:2012
ISSN:1559-0267 (Electronic)
Megjegyzések:Evidence points to an association of prolactin to autoimmune diseases. We examined the correlation between hyperprolactinemia and disease manifestations and activity in a large patient cohort. Age- and sex-adjusted prolactin concentration was assessed in 256 serum samples from lupus patients utilizing the LIASON prolactin automated immunoassay method (DiaSorin S.p.A, Saluggia, Italy). Disease activity was defined as present if European Consensus Lupus Activity Measurement (ECLAM) > 2 or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) > 4. Lupus manifestations were grouped by organ involvement, laboratory data, and prescribed medications. Hyperprolactinemia was presented in 46/256 (18%) of the cohort. Hyperprolactinemic patients had significantly more serositis (40% vs. 32.4%, p = 0.03) specifically, pleuritis (33% vs. 17%, p = 0.02), pericarditis (30% vs. 12%, p = 0.002), and peritonitis (15% vs. 0.8%, p = 0.003). Hyperprolactinemic subjects exhibited significantly more anemia (42% vs. 26%, p = 0.02) and marginally more proteinuria (65.5% vs. 46%, p = 0.06). Elevated levels of prolactin were not significantly associated with other clinical manifestations, serology, or therapy. Disease activity scores were not associated with hyperprolactinemia. Hyperprolactinemia in lupus patients is associated with all types of serositis and anemia but not with other clinical, serological therapeutic measures or with disease activity. These results suggest that dopamine agonists may be an optional therapy for lupus patients with hyperprolactinemia.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Reviews in Allergy and Immunology. - 42 : 2 (2012), p. 189-198. -
További szerzők:Zandman-Goddard, Gisele Boaz, Mona Agmon-Levin, Nancy Amital, Howard Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Rovensky, Josef Kiss Emese (1960-) (belgyógyász, immunológus) Doria, Andrea Ghirardello, A. Gomez-Arbesu, Jesus Stojanovich, Ljudmila Ingegnoli, Francesca Meroni, Pier Luigi Rozman, Blaz Blank, Marion Shoenfeld, Yehuda
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM007083
Első szerző:Soltész Pál (belgyógyász, kardiológus)
Cím:Cardiac manifestations in antiphospholipid syndrome / Soltesz, P., Szekanecz, Z., Kiss, E., Shoenfeld, Y.
Dátum:2007
ISSN:1568-9972 (Print)
Megjegyzések:Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Atherosclerosis
Autoantibodies
Cardiovascular Diseases
Humans
Risk Factors
Thrombosis
Megjelenés:Autoimmunity Reviews. - 6 : 6 (2007), p. 379-386. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:elektronikus változat
elektronikus változat
DOI
Borító:

7.

001-es BibID:BIBFORM001209
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus / Tarr T., Lakos G., Bhattoa H. P., Szegedi G., Shoenfeld Y., Kiss E.
Dátum:2007
Megjegyzések:The objective of this study was to analyse whether primary antiphospholipid syndrome (PAPS) may precede and modify the characteristics of systemic lupus erythematosus (SLE). Out of the total 362 SLE patients in our service, 223 patients had antiphospholipid antibodies (aPL), of whom 110 met the criteria of antiphospholipid syndrome. In 26 cases (7.2%) PAPS appeared 5.5 years before the onset of lupus (PAPS+SLE Group). Their clinical findings were compared to lupus patients without (SLE only Group, n=26) and with secondary APS (SLE+SAPS Group, n=26). The prevalence of deep venous thrombosis, stroke/TIA, recurrent fetal loss, coronary heart disease and myocardial infarction was significantly higher in PAPS+SLE Group as compared to SLE only Group. The difference in prevalence of fetal loss (P=0.014) between PAPS+SLE and SLE+SAPS Groups was also recorded. On comparison to PAPS+SLE Group, patients without APS (SLE only Group) were younger at onset of lupus, with more frequent flares and a higher prevalence of WHO type III/IV nephritis (P=0.007), requiring higher doses of cyclophosphamide and corticosteroids. Lupus started in the form of PAPS in 7.2% of our SLE patients, who presented with more thrombotic and less inflammatory complications than in SLE patients without a prior or with a following secondary APS. Considering the long latency between the two diseases, PAPS may be a forerunner of lupus, but it may also coexist with SLE as an independent autoimmune disorder
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
association
PAPS
SLE
Association
phospholipid antibody
adolescent
adult
antiphospholipid syndrome
article
deep vein thrombosis
female
fetus wastage
heart infarction
human
ischemic heart disease
major clinical study
male
nephritis
priority journal
recurrent disease
school child
stroke
systemic lupus erythematosus
transient ischemic attack
Adolescent
Adult
Antiphospholipid Syndrome
Child
Female
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Megjelenés:Lupus 16 : 5 (2007), p. 324-328. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:

8.

001-es BibID:BIBFORM001208
035-os BibID:PMID:17283584
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients / T. Tarr, G. Lakos, H. P. Bhattoa, Y. Shoenfeld, Gy. Szegedi, E. Kiss
Dátum:2007
Megjegyzések:The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (abeta2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL- group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL- patients who met the Sapporo criteria. LAC was more common in the APS than the aPL- group (32.1% versus 9.9%, P < 0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL- group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
antiphospholipid syndrome
primary prophylaxis
thrombosis
Primary prophylaxis
acetylsalicylic acid
beta2 glycoprotein 1 antibody
cardiolipin antibody
clopidogrel
coumarin
fibrinolytic agent
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
controlled study
disease duration
female
follow up
heart infarction
human
major clinical study
male
prevalence
priority journal
prophylaxis
risk assessment
risk factor
stroke
systemic lupus erythematosus
thrombocytopenia
thrombosis
Adult
Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Autoantigens
beta 2-Glycoprotein I
Cerebrovascular Accident
Female
Fibrinolytic Agents
Follow-Up Studies
Humans
Lupus Coagulation Inhibitor
Lupus Erythematosus, Systemic
Male
Middle Aged
Platelet Aggregation Inhibitors
Risk Factors
Thrombophilia
Thrombosis
egyetemen (Magyarországon) készült közlemény
Megjelenés:Lupus 16 : 1 (2007), p. 39-45. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Szerző által megadott URL
Borító:

9.

001-es BibID:BIBFORM001205
035-os BibID:PMID:17916982
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:2007
Megjegyzések:Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
thrombotic manifestation
APS
Follow-up
LAC
Primary prophylaxis
acetylsalicylic acid
antithrombocytic agent
beta2 glycoprotein 1 antibody
cardiolipin antibody
coumarin
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
cerebrovascular accident
cohort analysis
controlled study
data base
deep vein thrombosis
disease association
disease course
drug efficacy
female
follow uphigh risk population
history of medicine
human
international normalized ratio
lung embolism
major clinical study
male
medical record
prevalence
prophylaxis
prospective study
stroke
systemic lupus erythematosus
thrombosis
transient ischemic attack
Adult
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Aspirin
Cohort Studies
Female
Follow-Up Studies
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Thrombosis
Time Factors
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

10.

001-es BibID:BIBFORM015927
Első szerző:Zandman-Goddard, Gisele
Cím:Hyperferritinemia is Associated with Serologic Antiphospholipid Syndrome in SLE Patients / Zandman-Goddard, G., Orbach, H., Agmon-Levin, N., Boaz, M., Amital, H., Szekanecz, Z., Szucs, G., Rovensky, J., Kiss, E., Corocher, N., Doria, A., Stojanovich, L., Ingegnoli, F., Meroni, P. L., Rozman, B., Gomez-Arbesu, J., Blank, M., Shoenfeld, Y.
Dátum:2013
ISSN:1559-0267 (Electronic)
Megjegyzések:Ferritin may play a direct role on the immune system. We sought to determine if elevated levels of ferritin in lupus patients correlate with disease activity and organ involvement in a large cohort. Ferritin levels (gender and age adjusted) were assessed in 274 lupus serum samples utilizing the LIASON Ferritin automated immunoassay method. Significant disease activity was determined if European Consensus Lupus Activity Index (ECLAM) > 2 or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) > 4. Utilizing an EXCEL database, we compared elevated ferritin levels to manifestations grouped by organ involvement, serology, and previous therapy. The patients were predominantly female (89%), median age was 37 years old, and disease duration was 10.6 +/- 7.7 years. Hyperferritinemia was found in 18.6% of SLE patients. Compared to subjects with normal ferritin levels, a significantly greater proportion of patients with hyperferritinemia had thrombocytopenia (15.4% vs. 33.3%, p = 0.003) and lupus anticoagulant (11.3% vs. 29.0%, p = 0.01). Additionally, compared to normoferritinemic subjects, hyperferritinemic subjects had significantly higher total aCL (99.7 +/- 369 vs. 30.9 +/- 17.3 GPI, p = 0.02) and aCL IgM antibody levels (75.3 +/- 357.4 vs. 9.3 +/- 10.3 GPI, p = 0.02), and marginally lower aCL IgG antibody levels (9.2 +/- 4.9 vs. 9.7 +/- 3.9 GPI, p = 0.096). While the ECLAM score significantly correlated with hyperferritinemia (p = 0.04), the SLEDAI score was marginally associated with hyperferritinemia (p = 0.1). Serositis was marginally associated with hyperferritinemia, but not with other manifestations. An association with serologic APS was encountered. Hyperferritinemia was associated with thrombocytopenia, lupus anticoagulant, and anti-cardiolipin antibodies suggest that it may be an early marker for secondary antiphospholipid syndrome in SLE patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Reviews in Allergy and Immunology. - 44 : 1 (2013), p. 23-30. -
További szerzők:Orbach, Hedi Agmon-Levin, Nancy Boaz, Mona Amital, Howard Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Rovensky, Josef Kiss Emese (1960-) (belgyógyász, immunológus) Corocher, Nadia Doria, Andrea Stojanovich, Ljudmila Ingegnoli, Francesca Meroni, Pier Luigi Rozman, Blaz Gomez-Arbesu, Jesus Blank, Miri Shoenfeld, Yehuda
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1